A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma

BACKGROUND: The Notch pathway is frequently activated in cancer. Pathway inhibition by γ-secretase inhibitors has been shown to be effective in pre-clinical models of pancreatic cancer, in combination with gemcitabine. METHODS: A multi-centre, non-randomised Bayesian adaptive design study of MK-0752...

Descripción completa

Detalles Bibliográficos
Autores principales: Cook, Natalie, Basu, Bristi, Smith, Donna-Michelle, Gopinathan, Aarthi, Evans, Jeffry, Steward, William P, Palmer, Daniel, Propper, David, Venugopal, Balaji, Hategan, Mirela, Anthoney, D Alan, Hampson, Lisa V, Nebozhyn, Michael, Tuveson, David, Farmer-Hall, Hayley, Turner, Helen, McLeod, Robert, Halford, Sarah, Jodrell, Duncan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2018
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5877439/
https://www.ncbi.nlm.nih.gov/pubmed/29438372
http://dx.doi.org/10.1038/bjc.2017.495

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5877439/
https://www.ncbi.nlm.nih.gov/pubmed/29438372
http://dx.doi.org/10.1038/bjc.2017.495

Ejemplares similares